DMBT1 and lung disorder: Further studies that analyze longitudinal samples of patients with CF along with their clinical data or at least cross-sectional data of patients with predefined, different stages of CF lung disease are needed in order to establish DMBT1 as a biomarker to monitor progression of CF lung disease.